

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Knight, et al.
 Serial No. : 09/920,262 Art Unit:
 Filed : August 1, 2001 Examiner:
 For : Anti-IL-12 Antibodies, Compositions, Methods And Uses

4/a



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

February 22, 2002

(Date of Deposit)

Guy Kevin Townsend

Name of applicant, assignee, or Registered Representative

Guy K Townsend
 (Signature)

February 22, 2002

(Date of Signature)

Commissioner for Patents
 Washington, D.C. 20231

RESPONSE

Pursuant to the requirements of 37 CFR 1.822 and/or 1.823 and further to the office action dated October 23, 2001, Applicant submits a corrected copy of the Sequence Listing in computer readable form, including a printed version of the Sequence Listing of the subject application. As required, a copy of the Formalities Letter is also attached.

Furthermore, a Verified Statement concerning the enclosed diskette is submitted herewith.


If any fees are due in connection with the filing of this response, authorization is hereby given to charge the amount of such fee to Deposit Account No. 10-0750/CEN0248/GKT in the name of Johnson & Johnson.

Respectfully submitted,

Guy K Townsend

Guy Kevin Townsend
 Registration No. 34,033
 Attorney for Applicants

2/22/02
 Johnson & Johnson
 One Johnson & Johnson Plaza
 New Brunswick, NJ 08933-7003
 732.524.2517



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. Knight, et al.

Serial No. : 09/920,262

Art Unit:

Filed : August 1, 2001

Examiner:

For : Anti-IL-12 Antibodies, Compositions, Methods And Uses

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, D.C. 20231 on

February 22, 2002

(Date of Deposit)

Guy Kevin Townsend

Name of applicant, assignee, or Registered Representative



(Signature)

February 22, 2002

(Date of Signature)

Honorable Commissioner for Patents
Washington, D.C. 20231

Verified Statement Under 37 CFR §1.821(f)


I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of the Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Guy Kevin Townsend
Registration No. 34,033
Attorney for Applicant(s)

2/22/02
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
732.524.2517
Dated: February 22, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/920,262	08/01/2001	Joi Giles-Komar	CEN0248

CONFIRMATION NO. 5697

000027777

AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

FORMALITIES LETTER



OC000000006954128

Date Mailed: 10/23/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Jenette

RECEIVED
PATENT INFORMATION
SERVICES

NOV 15 2001

TO FILE REFER TO

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE